Together, we can ensure no myeloma patient in China fights alone.
At a Glance
CMDN collaborates with international myeloma advocacy groups, academic medical centers, public-interest foundations, and open-data technology teams, alongside bilingual medical and editorial volunteers. Clinical accuracy is reviewed by qualified partner specialists while community coordinators manage operations. CMDN upholds strict editorial independence and patient privacy—no grant or sponsorship can ever purchase patient data, commercial referrals, editorial control, or clinical trial ranking priority.
CMDN (China Myeloma Digital Network) is a nonprofit, patient-founded organization supporting 2,000+ multiple myeloma patients and families across China. We independently curate evidence-based resources and provide free, unbiased navigation for international patients seeking approved CAR-T therapies in China.
2,000+
Patients & Caregivers Supported
Active members in our patient community
50+
Evidence-Based Guidelines
Curated from NCCN, IMWG, CSCO & more
64
Active Clinical Trials
72 records in the full registry
2
Languages Supported
Full bilingual platform (中文 / English)
Methodology note: Community size and regional coverage reflect rounded operational records as of 2026-10-08; clinical trial figures are synchronized with our public snapshot generated on 2026-10-21. View Open Dataset & Methodology →
Our community represents a diverse cross-section of the myeloma patient population in China, offering authentic, first-hand perspectives on the Chinese treatment landscape.
Coverage
30+ provinces across mainland China
Composition
Patients, caregivers, and family members
Disease Stages
Newly diagnosed through relapsed/refractory
Engagement
Daily peer support and knowledge sharing
Content Focus
Evidence-based guidance, CAR-T navigation, and research records
Platform
WeChat groups + chinamyeloma.org (bilingual)
Bridging global myeloma science and grassroots patient communities across China with transparency and rigor.
Direct connection to 2,000+ actively engaged patients and caregivers, providing authentic patient voices and real-world insights from the Chinese myeloma landscape.
50+ authoritative clinical guidelines translated and localized for Chinese patients, sourced from NCCN, IMWG, CSCO, and other leading institutions.
The registry contains 72 myeloma trial records, including 64 actively recruiting studies across CAR-T, bispecific antibodies, and other emerging therapies.
Proven ability to translate global advocacy initiatives into locally impactful programs that resonate with Chinese patients and families.
Structured, non-commercial collaboration models designed to deliver measurable value to myeloma patients and families.
Co-develop or translate patient education materials, clinical guidelines, and awareness resources for the Chinese myeloma community.
Collaborate on global initiatives such as Myeloma Action Month, World Cancer Day, and regional awareness events with localized Chinese execution.
Share patient insights, real-world data, and community feedback to support global research and improve treatment outcomes.
Exchange advocacy best practices, organizational development strategies, and patient support program methodologies.
We highlight only publicly verifiable initiatives with open repositories or permanent archives. Citing public guidelines does not imply institutional endorsement by their original publishers.
Open Data Initiative
CMDN normalizes public registry records (including CDE and ChiCTR) into a structured, bilingual open dataset with a public schema dictionary, GitHub repository, and permanent Zenodo DOI.
Technology Infrastructure
CastMaster builds and maintains CMDN’s pro-bono digital infrastructure, powering bilingual evidence publishing, automated clinical trial snapshots, and patient navigation tools.
These four non-negotiable principles govern every partnership, grant, and editorial workflow at CMDN.
Our clinical trial registry and guideline summaries are curated objectively. Inclusion, ordering, and editorial conclusions are never influenced by commercial relationships.
All patient education and navigation support are provided free of charge. We strictly prohibit paid referrals, medical brokerage, or commercial lead generation.
Partner status never grants automatic access to patient lists, contact details, or medical records. Any research initiative requires explicit consent and ethics review.
Grants or resource support can never be exchanged for product endorsements, content intervention, exclusive arrangements, or priority clinical trial placement.
Accountability & Transparency
Maintained by the CMDN Operations Team and published by CMDN · China Myeloma Digital Network. Last reviewed on 2026-10-08 and updated whenever governance rules or registry snapshots change.
This page outlines partnership rules and does not constitute medical advice. Clinical content is reviewed by qualified partner specialists; a formal Medical Advisory Board is a planned governance milestone and is not represented as already established.
Explore our open datasets, bilingual clinical knowledge base, and independent navigation hubs available for academic and public-interest collaboration.
Structured registry records of myeloma trials in China, published with a data dictionary, GitHub repository, and Zenodo DOI.
50+ patient-friendly clinical guides localized from NCCN, IMWG, ESMO, and CSCO under an open CC BY-NC-SA 4.0 license.
Independent, nonprofit evidence hub covering approved CAR-T products, hospital tiers, pricing facts, and due-diligence checklists.
Our evidence-based content is built upon guidelines published by these leading global authorities. We independently curate and translate their publicly available clinical guidelines for Chinese patients:
Answers to common questions from international organizations, researchers, and prospective collaborators.
We collaborate with international myeloma advocacy organizations, academic medical centers, research institutions, public-interest foundations, open-data teams, and mission-aligned organizations committed to transparent governance.
No. CMDN is a nonprofit patient advocacy initiative. We never charge patients for navigation support, and we do not accept referral fees, commissions, or brokerage payments from hospitals, clinics, or third-party agencies.
No. Partnership status never grants automatic access to personal data, contact lists, or medical records. Any patient research or survey collaboration must serve a clear patient benefit, obtain explicit informed consent, and pass applicable ethics and privacy reviews.
Never. Grants and sponsorships cannot be exchanged for editorial control, product recommendations, exclusive arrangements, or priority placement in our clinical trial directory. All material support and potential conflicts of interest are publicly disclosed.
Please share your organization name and lead contact, the specific patient need you aim to address, proposed collaboration scope and timeline, whether patient outreach or data is involved, and any funding sources or potential conflicts of interest.
We welcome conversations with international myeloma organizations, research institutions, and advocacy groups. Reach out to explore how we can work together to improve outcomes for myeloma patients.
Reach out directly to our international collaboration team. We respond to institutional, academic, and public-interest inquiries within 3–5 business days.
General & volunteer inquiries: contact@chinamyeloma.org
What to Include
To help us evaluate alignment with our patient-first and editorial independence policies, please include:
